Angeli Davide, Salvi Samanta, Tedaldi Gianluca
Biostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.
Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.
Int J Mol Sci. 2020 Feb 8;21(3):1128. doi: 10.3390/ijms21031128.
Breast and ovarian cancers are some of the most common tumors in females, and the genetic predisposition is emerging as one of the key risk factors in the development of these two malignancies. and are the best-known genes associated with hereditary breast and ovarian cancer. However, recent advances in molecular techniques, Next-Generation Sequencing in particular, have led to the identification of many new genes involved in the predisposition to breast and/or ovarian cancer, with different penetrance estimates. , , , and have been identified as high penetrance genes for the risk of breast/ovarian cancers. Besides them, , , , , , , , , and mismatch repair genes have been recognized as moderate and low penetrance genes, along with other genes encoding proteins involved in the same pathways, possibly associated with breast/ovarian cancer risk. In this review, we summarize the past and more recent findings in the field of cancer predisposition genes, with insights into the role of the encoded proteins and the associated genetic disorders. Furthermore, we discuss the possible clinical utility of genetic testing in terms of prevention protocols and therapeutic approaches.
乳腺癌和卵巢癌是女性中最常见的一些肿瘤,遗传易感性正成为这两种恶性肿瘤发生的关键危险因素之一。BRCA1和BRCA2是与遗传性乳腺癌和卵巢癌相关的最知名基因。然而,分子技术的最新进展,特别是下一代测序,已导致鉴定出许多涉及乳腺癌和/或卵巢癌易感性的新基因,其外显率估计各不相同。PALB2、BRIP1、RAD51C和RAD51D已被确定为乳腺癌/卵巢癌风险的高外显率基因。除此之外,ATM、CHEK2、CDH1、STK11、PTEN、BRD7、BRD9、BARD1和错配修复基因已被认为是中度和低度外显率基因,以及其他编码参与相同途径的蛋白质的基因,可能与乳腺癌/卵巢癌风险相关。在本综述中,我们总结了癌症易感性基因领域过去和最近的发现,深入了解编码蛋白的作用和相关的遗传疾病。此外,我们从预防方案和治疗方法的角度讨论了基因检测的可能临床应用。